Protocol ID
COG # AREN0533
Protocol Description
Title
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Study
Description
The goals of this study are to see if patients with Stage III & IV favorable histology Wilms tumor that has only spread to the lungs can be treated with chemotherapy alone and if the lung tumors do not go away after 6 weeks of chemotherapy can they be given another 2 weeks of chemotherapy plus radation therapy to the lungs. Also if the Wilms tumor has spread to other parts of the body in addition to or instead of the lungs, the patient can be treated with 2 additional drugs along with the standard chemotherapy drugs and standard radiation therapy to all sites of disease.
Eligibility Criteria
- All patients must have Stage III or IV favorable histology Wilms tumor and enrolled on AREN03B2 Renal Tumor Biology and Classification Study before enrolling on this study confirmed by central pathology, surgical and radiology review.
- Patients must be less than 30 years old at the time of initial diagnosis.
- Patients must have adequate liver, and cardiac function as defined in the protocol.
Primary Investigator(s)
Mandy Atkinson, M.D.
Contact Information
Wendy McCarty, Research Coordinator
Office: 540-981-7376
wpmccarty@carilionclinic.org
for mail
for deliveries